Louise Frederika Kooij Sells 150,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

Key Points

• Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma, sold 150,000 shares at an average price of $25.83, significantly reducing her ownership in the company by approximately 90.91%.
• NewAmsterdam Pharma's stock recently rose by 1.1% to $26.90, with strong trading volume exceeding its average volume.
• The company reported earnings per share of ($0.15), outperforming expectations, and analysts anticipate a target price average of $41.55 for the stock.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the sale, the chief accounting officer owned 15,000 shares in the company, valued at $387,450. This represents a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, September 3rd, Louise Frederika Kooij sold 18,073 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.09, for a total transaction of $453,451.57.
• On Monday, August 25th, Louise Frederika Kooij sold 8,269 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $24.86, for a total transaction of $205,567.34.

NewAmsterdam Pharma Stock Up 1.1%

Shares of NASDAQ NAMS traded up $0.30 on Wednesday, hitting $26.90. The company's stock had a trading volume of 1,158,119 shares, compared to its average volume of 849,745. The stock has a 50 day moving average of $23.29 and a 200-day moving average of $20.66. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. The firm had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. Equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAMS. The Manufacturers Life Insurance Company acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth about $221,000. Northern Trust Corp purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $556,000. BNP Paribas Financial Markets acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $916,000. Bank of America Corp DE raised its holdings in NewAmsterdam Pharma by 1,506.2% in the fourth quarter. Bank of America Corp DE now owns 43,529 shares of the company's stock valued at $1,119,000 after buying an additional 40,819 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in NewAmsterdam Pharma by 12.7% in the fourth quarter. Janus Henderson Group PLC now owns 1,736,777 shares of the company's stock valued at $44,653,000 after buying an additional 196,048 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

Analysts Set New Price Targets

NAMS has been the subject of a number of recent research reports. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They set an "overweight" rating and a $45.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target for the company. Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target for the company. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.